Abiopharma

🔍 ZANTE GREG (Executive)

Company: Viking Therapeutics, Inc. (VKTX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 41,000 shares of Common Stock, par value $0.00001 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 215,483.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 32,049 shares of Common Stock, par value $0.00001 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 247,532.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 31,961 shares of Common Stock, par value $0.00001 per share at $32.295 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 215,571.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 13,900 shares of Common Stock, par value $0.00001 per share at $33.3828 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 201,671.00 | transaction_form_type: 4 | Footnotes: F4, F6
• Sold 10,300 shares of Common Stock, par value $0.00001 per share at $34.2364 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 191,371.00 | transaction_form_type: 4 | Footnotes: F4, F7
• Sold 1,500 shares of Common Stock, par value $0.00001 per share at $32.0887 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 189,891.00 | transaction_form_type: 4 | Footnotes: F4, F8
• Acquired 91,000 shares of Stock Option (Right to Buy) at $35.42 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: false | shares_owned_after: 91,000.00 | transaction_form_type: 4 | Footnotes: F9

Footnotes:

• F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
• F2: Includes 104 shares acquired on May 20, 2025 and 787 shares acquired on November 20, 2025 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
• F3: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal.
• F4: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3.
• F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F8: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F9: 25% of the shares subject to the option will vest on each anniversary of the grant date.